TGFB2 and melanoma: We also found that the co‐transplantation of the TGF‐β2‐treated TECs (End‐MyoT TECs) with A375 human melanoma cells to immunodeficient mice resulted in the formation of tumors with a greater size than the TECs treated with TGF‐β2 and FGF2 (End‐N‐MyoT TECs; Fig. 6), suggesting that TECs that are conferred with myofibroblastic properties behave as the tumor‐promoting CAFs.